ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health. In addition, the company provides contract manufacturing services of OTC healthcare and dietary supplements products. It markets its products through national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Doylestown, Pennsylvania.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRPH
CUSIPN/A
Phone215-345-0919
Debt
Debt-to-Equity RatioN/A
Current Ratio12.29
Quick Ratio10.79
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.87 million
Price / Sales3.51
Cash Flow$1.2265 per share
Price / Cash2.45
Book Value$2.56 per share
Price / Book1.17
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$40.58 million
Net Margins-8.88%
Return on Equity-3.81%
Return on Assets-3.56%
Miscellaneous
Employees46
Outstanding Shares11,540,000
Market Cap$34.63 million
ProPhase Labs (NASDAQ:PRPH) Frequently Asked Questions
What is ProPhase Labs' stock symbol?
ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH."
How often does ProPhase Labs pay dividends? What is the dividend yield for ProPhase Labs?
ProPhase Labs declared a special dividend on Wednesday, May 9th. Shareholders of record on Monday, May 21st will be given a dividend of $1.00 per share on Tuesday, June 5th. The ex-dividend date is Friday, May 18th. View ProPhase Labs' Dividend History.
How will ProPhase Labs' stock buyback program work?
ProPhase Labs announced that its Board of Directors has approved a share repurchase plan on Saturday, November 11th 2017, which authorizes the company to buyback 1,700,000 outstanding shares, according to EventVestor. This buyback authorization authorizes the company to reacquire shares of its stock through a tender offer. Stock buyback plans are usually an indication that the company's management believes its stock is undervalued.
How were ProPhase Labs' earnings last quarter?
ProPhase Labs Inc (NASDAQ:PRPH) posted its quarterly earnings results on Monday, August, 20th. The company reported ($0.02) EPS for the quarter. The company had revenue of $3.19 million for the quarter. ProPhase Labs had a negative return on equity of 3.81% and a negative net margin of 8.88%. View ProPhase Labs' Earnings History.
When is ProPhase Labs' next earnings date?
Who are some of ProPhase Labs' key competitors?
Some companies that are related to ProPhase Labs include XOMA (XOMA), Chembio Diagnostics (CEMI), CytoDyn (CYDY), Forward Pharma A/S (FWP), Sierra Oncology (SRRA), Provention Bio (PRVB), Conatus Pharmaceuticals (CNAT), Juniper Pharmaceuticals (JNP), BioXcel Therapeutics (BTAI), Steadymed (STDY), ContraFect (CFRX), TapImmune (TPIV), Intec Pharma (NTEC), Trevena (TRVN) and Zynerba Pharmaceuticals (ZYNE).
Who are ProPhase Labs' key executives?
ProPhase Labs' management team includes the folowing people:
- Mr. Ted William Karkus, Chairman, CEO & Director (Age 59)
- Ms. Monica Brady, Chief Accounting Officer (Age 41)
Has ProPhase Labs been receiving favorable news coverage?
News coverage about PRPH stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. ProPhase Labs earned a coverage optimism score of 0.18 on Accern's scale. They also gave media coverage about the company an impact score of 46.57 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. View Recent Headlines for ProPhase Labs.
Who are ProPhase Labs' major shareholders?
ProPhase Labs' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.64%). Company insiders that own ProPhase Labs stock include Braden Michael Leonard, Jason Michael Barr, Robert V Cuddihy Jr and Ted William Karkus. View Institutional Ownership Trends for ProPhase Labs.
Which institutional investors are buying ProPhase Labs stock?
How do I buy shares of ProPhase Labs?
Shares of PRPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ProPhase Labs' stock price today?
One share of PRPH stock can currently be purchased for approximately $3.0050.
How big of a company is ProPhase Labs?
ProPhase Labs has a market capitalization of $34.63 million and generates $9.87 million in revenue each year. ProPhase Labs employs 46 workers across the globe.
How can I contact ProPhase Labs?
ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The company can be reached via phone at 215-345-0919 or via email at [email protected]
MarketBeat Community Rating for ProPhase Labs (NASDAQ PRPH)
MarketBeat's community ratings are surveys of what our community members think about ProPhase Labs and other stocks. Vote "Outperform" if you believe PRPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
